SFI
NKTR icon

Susquehanna Fundamental Investments’s Nektar Therapeutics NKTR Stock Holding History

Susquehanna Fundamental Investments’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-8,213
Closed -$73.4K – 238
2023
Q3 		$73.4K Sell
8,213
-2,039
-20% -$19.6K ﹤0.01% 349
2023
Q2 		$88.5K Hold
10,252
– – ﹤0.01% 611
2023
Q1 		$108K Hold
10,252
– – ﹤0.01% 899
2022
Q4 		$348K Buy
+10,252
New +$496K 0.01% 955

Other funds holding NKTR

DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MAM
Monaco Asset Management Monaco $542M AUM 54.4% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Susquehanna Fundamental Investments's NKTR Position: Q4 2023 in Review

Susquehanna Fundamental Investments sold out of Nektar Therapeutics (NKTR) in Q4 2023, closing a stake of 8,213 shares — an estimated $73.4K sold.

Susquehanna Fundamental Investments first reported a position in NKTR in Q4 2022 and held it in 4 quarters. The position peaked at $348K in Q4 2022. 125 funds tracked by Wall St. Rank hold NKTR as of Q4 2023.

  • Susquehanna Fundamental Investments reported no remaining Nektar Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Susquehanna Fundamental Investments sold 8,213 Nektar Therapeutics shares in Q4 2023, an estimated $73.4K.
  • Susquehanna Fundamental Investments first reported a position in Nektar Therapeutics in Q4 2022 and held it in 4 quarters.
  • Susquehanna Fundamental Investments's Nektar Therapeutics position peaked at $348K in Q4 2022.
  • 125 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q4 2023.

Based on Susquehanna Fundamental Investments's 13F filing for Q4 2023, filed 14 Feb 2024.